BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis

NASDAQ:BIOX • KYG1117K1141

0.459 USD
-0.1 (-18.04%)
At close: Mar 2, 2026
0.45 USD
-0.01 (-1.96%)
After Hours: 3/2/2026, 8:04:12 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BIOX scores 3 out of 10 in our fundamental rating. BIOX was compared to 83 industry peers in the Chemicals industry. BIOX has a bad profitability rating. Also its financial health evaluation is rather negative. BIOX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • BIOX had negative earnings in the past year.
  • BIOX had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
BIOX Yearly Net Income VS EBIT VS OCF VS FCFBIOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.67%, BIOX is doing worse than 79.52% of the companies in the same industry.
  • BIOX's Return On Equity of -21.79% is on the low side compared to the rest of the industry. BIOX is outperformed by 73.49% of its industry peers.
  • BIOX's Return On Invested Capital of 0.61% is on the low side compared to the rest of the industry. BIOX is outperformed by 72.29% of its industry peers.
Industry RankSector Rank
ROA -7.67%
ROE -21.79%
ROIC 0.61%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
BIOX Yearly ROA, ROE, ROICBIOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • BIOX has a Operating Margin of 1.27%. This is in the lower half of the industry: BIOX underperforms 72.29% of its industry peers.
  • With an excellent Gross Margin value of 40.62%, BIOX belongs to the best of the industry, outperforming 85.54% of the companies in the same industry.
  • BIOX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.27%
PM (TTM) N/A
GM 40.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
BIOX Yearly Profit, Operating, Gross MarginsBIOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIOX is destroying value.
  • The number of shares outstanding for BIOX has been increased compared to 1 year ago.
  • Compared to 5 years ago, BIOX has more shares outstanding
  • The debt/assets ratio for BIOX is higher compared to a year ago.
BIOX Yearly Shares OutstandingBIOX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BIOX Yearly Total Debt VS Total AssetsBIOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • BIOX has a debt to FCF ratio of 5.58. This is a neutral value as BIOX would need 5.58 years to pay back of all of its debts.
  • BIOX has a Debt to FCF ratio of 5.58. This is in the better half of the industry: BIOX outperforms 75.90% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that BIOX is not too dependend on debt financing.
  • BIOX has a better Debt to Equity ratio (0.26) than 78.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.58
Altman-Z N/A
ROIC/WACC0.11
WACC5.62%
BIOX Yearly LT Debt VS Equity VS FCFBIOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that BIOX may have some problems paying its short term obligations.
  • BIOX's Current ratio of 0.94 is on the low side compared to the rest of the industry. BIOX is outperformed by 91.57% of its industry peers.
  • BIOX has a Quick Ratio of 0.94. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.65, BIOX is not doing good in the industry: 89.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.65
BIOX Yearly Current Assets VS Current LiabilitesBIOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • BIOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2230.77%.
  • Looking at the last year, BIOX shows a very negative growth in Revenue. The Revenue has decreased by -27.90% in the last year.
  • The Revenue has been growing by 14.10% on average over the past years. This is quite good.
EPS 1Y (TTM)-2230.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-27.9%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-16.52%

3.2 Future

  • BIOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.67% yearly.
  • Based on estimates for the next years, BIOX will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BIOX Yearly Revenue VS EstimatesBIOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BIOX Yearly EPS VS EstimatesBIOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BIOX. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 1.96, the valuation of BIOX can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BIOX indicates a rather cheap valuation: BIOX is cheaper than 100.00% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.11. BIOX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 1.96
BIOX Price Earnings VS Forward Price EarningsBIOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

  • 61.45% of the companies in the same industry are more expensive than BIOX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BIOX is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.63
EV/EBITDA 10.33
BIOX Per share dataBIOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.42%
EPS Next 3Y39.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIOX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOCERES CROP SOLUTIONS CORP

NASDAQ:BIOX (3/2/2026, 8:04:12 PM)

After market: 0.45 -0.01 (-1.96%)

0.459

-0.1 (-18.04%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-05
Earnings (Next)N/A
Inst Owners31.13%
Inst Owner Change0.92%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap29.14M
Revenue(TTM)318.16M
Net Income(TTM)-56.37M
Analysts43.33
Price Target2.04 (344.44%)
Short Float %1.32%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP-0.13%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-538.65%
Min EPS beat(2)-1015.03%
Max EPS beat(2)-62.27%
EPS beat(4)1
Avg EPS beat(4)-270.05%
Min EPS beat(4)-1015.03%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-295.97%
EPS beat(12)2
Avg EPS beat(12)-113.26%
EPS beat(16)3
Avg EPS beat(16)-102.76%
Revenue beat(2)0
Avg Revenue beat(2)-25.21%
Min Revenue beat(2)-34.42%
Max Revenue beat(2)-16.01%
Revenue beat(4)0
Avg Revenue beat(4)-19.16%
Min Revenue beat(4)-34.42%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-12.83%
Revenue beat(12)2
Avg Revenue beat(12)-9.34%
Revenue beat(16)6
Avg Revenue beat(16)1.35%
PT rev (1m)0%
PT rev (3m)-62.35%
EPS NQ rev (1m)-6.67%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)44.83%
EPS NY rev (3m)36%
Revenue NQ rev (1m)-8.18%
Revenue NQ rev (3m)-8.18%
Revenue NY rev (1m)-4.26%
Revenue NY rev (3m)-11.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.96
P/S 0.09
P/FCF 0.63
P/OCF 0.49
P/B 0.11
P/tB N/A
EV/EBITDA 10.33
EPS(TTM)-0.83
EYN/A
EPS(NY)0.23
Fwd EY51.11%
FCF(TTM)0.73
FCFY158.87%
OCF(TTM)0.93
OCFY202.93%
SpS5.01
BVpS4.07
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.67%
ROE -21.79%
ROCE 0.93%
ROIC 0.61%
ROICexc 0.63%
ROICexgc 2.08%
OM 1.27%
PM (TTM) N/A
GM 40.62%
FCFM 14.55%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.58
Debt/EBITDA 2.49
Cap/Depr 56.55%
Cap/Sales 4.04%
Interest Coverage 0.22
Cash Conversion 221.17%
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.65
Altman-Z N/A
F-Score4
WACC5.62%
ROIC/WACC0.11
Cap/Depr(3y)96.4%
Cap/Depr(5y)121.83%
Cap/Sales(3y)4.91%
Cap/Sales(5y)4.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2230.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-27.9%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-16.52%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-89.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.92%
FCF growth 3YN/A
FCF growth 5Y38.53%
OCF growth 1Y18.95%
OCF growth 3YN/A
OCF growth 5Y34.31%

BIOCERES CROP SOLUTIONS CORP / BIOX FAQ

What is the ChartMill fundamental rating of BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOX.


Can you provide the valuation status for BIOCERES CROP SOLUTIONS CORP?

ChartMill assigns a valuation rating of 6 / 10 to BIOCERES CROP SOLUTIONS CORP (BIOX). This can be considered as Fairly Valued.


How profitable is BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

BIOCERES CROP SOLUTIONS CORP (BIOX) has a profitability rating of 2 / 10.


Can you provide the financial health for BIOX stock?

The financial health rating of BIOCERES CROP SOLUTIONS CORP (BIOX) is 2 / 10.